Newstral
John Maraganore
- MAlnylam's shares rise on late-stage rare disease resultsmarketwatch.com
- Regeneron partners with Alnylam to pursue liver disease treatmentwestfaironline.com
- MAlnylam stock more than tripled last year — and the company says 2018 will be bigmarketwatch.com
- Merck CEO resigns from Trump council over Charlottesvillemetro.us
- MAlnylam Pharma stock plummets 45% after discontinuing drug on patient safety concernsmarketwatch.com
- Alnylam trial confirms continued effectiveness of RNAi drugsbizjournals.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.